戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1                              None was taking psychotropic medication.
2 tment are most likely to receive concomitant psychotropic medication.
3 sychiatric facilities were given concomitant psychotropic medication.
4 ents, and patients who were not prescribed a psychotropic medication.
5 re not depressed, and none had ever received psychotropic medication.
6 diagnosis and 422 080 with a prescription of psychotropic medication.
7 on-deficit/hyperactivity disorder and use of psychotropic medication.
8 n antipsychotic drug treatment with a second psychotropic medication.
9 tal disorder or had a filled prescription of psychotropic medication.
10 nces were found in patients currently taking psychotropic medication.
11 present whether or not the participant takes psychotropic medication.
12 e the likelihood of off-label prescribing of psychotropic medication.
13 pression is associated with being prescribed psychotropic medication.
14 ic disorder, current depression, and current psychotropic medication.
15 were not using any mental health services or psychotropic medications.
16  of individuals with dose increases in their psychotropic medications.
17 ied by a commensurate increase in the use of psychotropic medications.
18 tions, new prescriptions, or daily doses for psychotropic medications.
19 and increased public acceptance of effective psychotropic medications.
20 e course of 10 years to examine their use of psychotropic medications.
21 treatment for weight gain in patients taking psychotropic medications.
22  physicians and provided in conjunction with psychotropic medications.
23 milar regions of the brain, or the effect of psychotropic medications.
24 ohol abuse or dependence, and current use of psychotropic medications.
25  antidepressants, or other nonantidepressant psychotropic medications.
26 d in increased prescription rates of certain psychotropic medications.
27 s as evidenced by increased prescriptions of psychotropic medications.
28 racting comedications, and concurrent use of psychotropic medications.
29 sed, including visits associated with use of psychotropic medications.
30 iatric MH services while limiting the use of psychotropic medications.
31 ithout mental disorders and those not taking psychotropic medications.
32 actures based on mental disorders and use of psychotropic medications.
33 milar patterns were found for treatment with psychotropic medications.
34 articipants were weight-restored and free of psychotropic medications.
35 K3beta activity contributes to the action of psychotropic medications.
36 pulation or among control groups using other psychotropic medications.
37              Adjustments were made for other psychotropic medications.
38 ht also exhibit changes after treatment with psychotropic medications.
39 nstrated following administration of several psychotropic medications.
40 ation services, neurologic events, or use of psychotropic medications.
41  with versus those without prescribed use of psychotropic medication (0.93 [0.92-0.95]), with the str
42 any mental or behavioural disorder or use of psychotropic medication (1.58 [1.48-1.69]), and suicidal
43 experienced lower prescription rates for any psychotropic medication (12.6 [95% CI, 4.6%-20.6%]).
44 der (22.5% vs 5.8%; P = .005), and receiving psychotropic medications (18.0% vs 4.7%; P = .007), intr
45 s before the cancer death/index date, use of psychotropic medication 6 months before the cancer death
46 oms were more likely to have been prescribed psychotropic medication (adjusted odds ratio = 1.9; 95%,
47 sors for exploration and characterization of psychotropic medication adverse effects.
48  total brain volume, age, gender, education, psychotropic medications, alcohol use, and race/ethnicit
49 rates of all known psychiatric illnesses and psychotropic medications among all suicide profiles.
50 e of the most commonly prescribed classes of psychotropic medications among US youths.
51  Tenth Revision, codes F00-F99) and redeemed psychotropic medication (Anatomical Therapeutic Chemical
52 ehavior disorders as well as nonadherence to psychotropic medication and lower socioeconomic levels.
53                                       Use of psychotropic medication and presence of comorbid major d
54  both relative to patients not receiving any psychotropic medication and relative to their pretreatme
55 effect persisted after covarying for current psychotropic medication and severity of current depressi
56 ated the relative mortality, prescription of psychotropic medication and use of primary medical care
57 -SSRI antidepressants, and nonantidepressant psychotropic medications and analyses in the clinically
58 were found among individuals with or without psychotropic medications and family history of cardiovas
59 riod of expansion in the number of available psychotropic medications and growth in managed behaviora
60  Before treatment, all subjects were free of psychotropic medications and had a score </=20 on the Ce
61                                  Maintenance psychotropic medications and supportive psychotherapy we
62 te the associations between major classes of psychotropic medications and violent reoffending.
63  human resources, rehabilitation facilities, psychotropic medication, and community mental health as
64 duration of inpatient admissions, the use of psychotropic medication, and self-report measures of dep
65 rimary care physicians prescribe concomitant psychotropic medication, and they show great variability
66  using mental health services (talk therapy, psychotropic medication, and/or a support group), most c
67 er involvement of physicians, greater use of psychotropic medications, and expanding availability of
68  antiarrhythmic agents, antimicrobial drugs, psychotropic medications, and methadone, as well as a gr
69 12-month mental disorder had been prescribed psychotropic medications, and most had evidence of psych
70 otic or manic symptoms, no use of concurrent psychotropic medications, and no current dependence on i
71 e associated with poorer response to certain psychotropic medications, and our previous work suggeste
72 ds with or without dispensed prescription of psychotropic medications (antipsychotics, antidepressant
73 Despite their nonnegligible adverse effects, psychotropic medications are a common cost-effective app
74 information on mental health service use and psychotropic medications are scarce.
75                                              Psychotropic medications are widely prescribed, but how
76 f comorbid major depressive disorder, use of psychotropic medications, assay used, and time of day bl
77 , most patients in these studies were taking psychotropic medications at the time of PPI testing, and
78 ealed to be seemingly driven by those taking psychotropic medications (BD-med).
79 diagnosis of MDD, not currently treated with psychotropic medication, between ages of 18 and 65 (mean
80 ncidence of arrhythmia in patients receiving psychotropic medication by monitoring of electrocardiogr
81 ed a psychiatric diagnosis or treatment with psychotropic medications by ages 16-17.
82 scribes the prevalence and pattern of use of psychotropic medications by HIV-positive patients receiv
83          Abrupt discontinuation of long-term psychotropic medication can be followed by a high risk o
84                  Analyses were stratified by psychotropic medication class (antipsychotic, anxiolytic
85 erformed to assess risk of fetal exposure by psychotropic medication class.
86  in prescribing trends were observed for all psychotropic medication classes after the pandemic onset
87 tion rates rose above those expected for all psychotropic medication classes except psychostimulants
88 the evidence on discontinuation of six major psychotropic medication classes: antidepressants, antips
89 e=1.3%, 95% CI=-0.7, 3.4), while use of only psychotropic medication declined (67.6% and 62.1%; adjus
90 rdoses involving sedative/hypnotic drugs and psychotropic medications decreased in frequency.
91 ecently diagnosed OCD who had never received psychotropic medication demonstrated no cognitive impair
92 primary outcomes were trends and patterns of psychotropic medication dispensation (including antipsyc
93 is cohort study found an increasing trend in psychotropic medication dispensation among children and
94                       Between 2006 and 2019, psychotropic medication dispensation increased from 0.85
95 sions to terminate a pregnancy if prescribed psychotropic medication during early pregnancy than if n
96     Opioids are frequently coprescribed with psychotropic medication during pregnancy and are associa
97                  Given concerns about use of psychotropic medication during pregnancy, the authors re
98 otic symptoms (47.6%) had taken a prescribed psychotropic medication during the last month.
99 onth), 4.1% of whom had a prescription for a psychotropic medication during the study period.
100  a mental health disorder or were prescribed psychotropic medication during their lifetime, which was
101 predict mental health service use and use of psychotropic medications during adolescence.
102                                       Use of psychotropic medications during pregnancy is appropriate
103    Weighing risks and benefits of the use of psychotropic medications during pregnancy remains a chal
104 ionship, such as genetic factors, the use of psychotropic medications during pregnancy, the timing wi
105 U.S. prescriptions (156.9 million claims for psychotropic medications during the study period) and a
106  and with treatment with specific classes of psychotropic medications (e.g., antidepressants, antipsy
107 ng participants who did not voluntarily take psychotropic medication, even minor assaultiveness was a
108                                              Psychotropic medication exposure has been shown to alter
109 re present early in life, are not related to psychotropic medication exposure, and are sex specific.
110 dedness-, and education-matched HCs, free of psychotropic medication for at least 12 weeks, viewed 60
111                All subjects had been free of psychotropic medication for at least 4 weeks.
112              The data supporting concomitant psychotropic medication for youths are almost exclusivel
113 dentify available information on concomitant psychotropic medication for youths.
114   These findings suggest that prescribing of psychotropic medications for children and adolescents in
115                 Recent reports on the use of psychotropic medications for preschool-aged children wit
116 ormation on the relative efficacy of various psychotropic medications for the treatment of DB, and in
117 eview of the comparative efficacy of various psychotropic medications for the treatment of disruptive
118 d symptomatologic phenotypes, we included 97 psychotropic-medication free adolescents with mood and a
119 a clinical research facility completed by 75 psychotropic medication-free patients with remitted MDD
120 d prescriptions for each of the 5 classes of psychotropic medications from January 1, 2007, to Decemb
121 use of psychotherapy (from 4.2% to 6.0%) and psychotropic medications (from 5.5% to 8.9%), including
122 o the prevalence and patterns of concomitant psychotropic medication given to youths with emotional a
123 the overall prescribing of non-antipsychotic psychotropic medications grew from 75.0% to 81.1%.
124 illed a prescription for a drug from another psychotropic medication group within the prior 6 months.
125  elements of detailed first-episode-specific psychotropic medication guidelines and a computerized de
126                Although mortality related to psychotropic medications has received much attention in
127 re widely prescribed, but how new classes of psychotropic medications have affected prescribing patte
128                                   Many other psychotropic medications have been considered and used t
129                                      Several psychotropic medications have been identified as potenti
130                                              Psychotropic medications have minimal evidence of effica
131 rated the influence of factors like usage of psychotropic medications, history of psychiatric hospita
132 .57]; p < 0.001) or a filled prescription of psychotropic medication (HR = 1.67; 95% CI [1.55, 1.79];
133 c with mental health, but data on the use of psychotropic medication in children and adolescents afte
134 tigating the association between exposure to psychotropic medication in pregnancy and any adverse hea
135 % reported that they had been treated with a psychotropic medication in the past 12 months.
136 harmacodynamics, and side-effect profiles of psychotropic medication in this population.
137 stimated 27.2% of HIV-positive patients took psychotropic medications in 1996.
138 e 1955 was conducted to determine the use of psychotropic medications in breast-feeding women.
139       No controlled studies on the safety of psychotropic medications in nursing mothers were found.
140 over widespread overmedication and misuse of psychotropic medications in US youth.
141                             Prescriptions of psychotropic medications, including antidepressants, ant
142             Rates of filled prescriptions of psychotropic medications, including antipsychotics, anxi
143 95% CI=0.59-0.90) declined while use of only psychotropic medication increased (44.1% and 57.4%; adju
144 hat treatment of MEFs with lithium (a common psychotropic medication) inhibits GAG sulfation and that
145 tics were performed to compare each class of psychotropic medications initiated and psychiatric diagn
146  There was no major difference in a class of psychotropic medications initiated by nurse practitioner
147  the odds of having a type of prescriber for psychotropic medication initiation for youths who receiv
148 tion-deficit/hyperactivity disorder [ADHD]), psychotropic medication initiation, and history of neuro
149 ctual disability have behaviour problems and psychotropic medication is a commonly used management st
150 g disorder; in the case of anorexia nervosa, psychotropic medication is generally reserved for patien
151                                         When psychotropic medication is used during breast-feeding, i
152                               Treatment with psychotropic medications is associated with altered gut
153                                    Combining psychotropic medications is common for people diagnosed
154                Rapid discontinuation of some psychotropic medications is followed by discontinuation
155                          Finally, the use of psychotropic medications is not unusual in personality d
156    Despite evidence of the increasing use of psychotropic medications, little is known about the broa
157                               Numerous other psychotropic medications may be considered, alone or in
158                               Treatment with psychotropic medications may contribute to obesity in wa
159 BD and offer preliminary evidence suggesting psychotropic medications may differentially influence br
160 , lifestyle, pregnancy, psychiatric illness, psychotropic medication, medical-seeking behavior, and f
161                                         Many psychotropic medications must be considered when treatin
162     Oculomotor tests were administered to 18 psychotropic medication-naive, nondepressed patients wit
163  but few studies, that examine the effect of psychotropic medication on anxiety disorders in children
164 e-blind placebo-controlled trial (Effects of Psychotropic Medication on Brain Development-Methylpheni
165 ignificant effect or ameliorative effects of psychotropic medications on abnormal structural and func
166 egarding the effects of prenatal exposure to psychotropic medications on fetal outcome.
167 linical studies have demonstrated effects of psychotropic medications on PPI.
168 er Lhx6 mRNA levels were not attributable to psychotropic medications or illness chronicity.
169   These differences were not attributable to psychotropic medications or other comorbid factors.
170 lth conditions with only psychotherapy, only psychotropic medication, or their combination; the mean
171           All subjects were free of alcohol, psychotropic medications, or drugs of abuse.
172 ealth patients receiving psychotherapy only, psychotropic medications, or their combination.
173 nary frequency or leaking (P = .006), use of psychotropic medication (P = .009), and denial of life a
174  health diagnoses (P = 0.019) and the use of psychotropic medications (P = 0.015) were significantly
175 ases in the use of and costs associated with psychotropic medications, particularly for youths with m
176                                              Psychotropic medication polypharmacy is common in psychi
177 tact mental health disorder diagnosis or any psychotropic medication prescribed at least 2 times, and
178 cluding a hospital-contact diagnosis, or any psychotropic medication prescribed by physicians, includ
179       There was an increase in the number of psychotropic medications prescribed across years; visits
180 fficacy, we compared the efficacy of various psychotropic medications prescribed for DB symptoms base
181                       In all 3 data sources, psychotropic medications prescribed for preschoolers inc
182 vestigated milder mental illness (ie, use of psychotropic medications prescribed in primary care with
183                                              Psychotropic medications prescribed prior to COVID-19 te
184  compared NAVIGATE and community care on the psychotropic medications prescribed, side effects experi
185 ommon mental illness, episodes of self-harm, psychotropic medication prescribing, and general practit
186 y, 4.8% [95% CI, 1.9%-7.7%]), and use of any psychotropic medication prescription (Latinx, 11.6% [95%
187  Longitudinal Neuropsychiatric Inventory and psychotropic medication prescription data from neuropath
188 on, substance use-related utilization, and a psychotropic medication prescription.
189                                All 8 839 143 psychotropic medication prescriptions dispensed to child
190                             Monthly rates of psychotropic medication prescriptions exceeded the expec
191  interrupted time-series analysis to compare psychotropic medication prescriptions in the 6 weeks bef
192                             Monthly rates of psychotropic medication prescriptions per 1000 children
193  January 2016, the estimated rate of monthly psychotropic medication prescriptions was 9.9 per 1000 c
194                          In total, 8 839 143 psychotropic medication prescriptions were analyzed, 5 8
195 3 months, falls, fall-related fractures, and psychotropic medication prescriptions.
196 rences in falls, fall-related fractures, and psychotropic medication prescriptions.
197 n mental disorder diagnoses, prescription of psychotropic medications, provision of psychotherapy, or
198  interactions between the gut microbiome and psychotropic medications (psycho-pharmacomicrobiomics) c
199 c treatment lasted 6 months and consisted of psychotropic medication, psychoeducation, and brief supp
200 ing in California MSAs with prescriptions of psychotropic medications recorded in the Merative Market
201 36 healthy control (HC) participants free of psychotropic medication recruited from several psychiatr
202  altered eating behavior, or side effects of psychotropic medication remains unclear.
203  small case series for each of the different psychotropic medications serve as the basis for suggeste
204 June 2022, the rate of incident users of any psychotropic medication showed a relative increase of 18
205                Most of the evidence on other psychotropic medications such as antidepressants, mood s
206                                              Psychotropic medications target glycogen synthase kinase
207 randomized clinical trials (RCTs) of various psychotropic medications targeting symptoms of DBs and a
208 nt mental health services, and on prescribed psychotropic medications through ages 16-17.
209  psychotherapy, but not in psychotherapy and psychotropic medication together (20.8% and 22.5%; adjus
210 % CI=0.48-0.90) as well as psychotherapy and psychotropic medication together (40.0% and 32.1%; adjus
211 )) locus (HTR2A), previously associated with psychotropic medication treatment outcome.
212 t a major issue is the potential confound of psychotropic medication upon experimental measures.
213                     Both sex (p = 0.003) and psychotropic medication usage (p = 0.025) are associated
214 telligence quotient and after accounting for psychotropic medication usage and comorbid psychopatholo
215  and was negatively associated with rates of psychotropic medication use (DID, -0.4%; 95% CI -0.7% to
216              This study examined patterns of psychotropic medication use after the Sept. 11, 2001, te
217 after the COVID-19 pandemic, particularly in psychotropic medication use and clinical outpatient, sch
218                      The association between psychotropic medication use and MI is probably a reflect
219 ates of new (incident) and total (prevalent) psychotropic medication use and psychiatric diagnoses we
220 wed similar trends of an overall increase in psychotropic medication use and psychiatric disorders.
221                               Depression and psychotropic medication use are potential risk indicator
222 y mental disorders during the 3 prior years, psychotropic medication use during the prior year, and i
223 ffects on decreasing behavioral symptoms and psychotropic medication use in dementia residents in lon
224                              The patterns of psychotropic medication use in outpatient medical practi
225 e of adverse health outcomes associated with psychotropic medication use in pregnant people with ment
226 ssessed the strength of associations between psychotropic medication use in pregnant people with ment
227                                              Psychotropic medication use in the past 12 months.
228 isk of incident MI and evaluates the role of psychotropic medication use in this relationship.
229 en observed and expected numbers of incident psychotropic medication use or psychiatric diagnoses fro
230 episode, dysphoria (2 weeks of sadness), and psychotropic medication use were assessed in 1981, and s
231 mine the association of mental disorders and psychotropic medication use with osteoporotic fracture r
232 fined by a clinical diagnosis and prescribed psychotropic medication use), HPV vaccine uptake (first
233  for major depressive disorder, were free of psychotropic medication use, and had a baseline 17-item
234  for major depressive disorder, were free of psychotropic medication use, and had a baseline 17-item
235 ma exposure, lifetime psychiatric diagnoses, psychotropic medication use, FKBP5 rs1360780 genotype, F
236 over time by provider specialty, concomitant psychotropic medication use, number of annual visits, an
237 were not affected by non-BD psychopathology, psychotropic medication use, or symptomatology.
238         A similar pattern was seen regarding psychotropic medication use, with a decreased risk in th
239 iagnoses, conventional CVD risk factors, and psychotropic medication use.
240 tment (ED) visits, inpatient admissions, and psychotropic medication use.
241 ore rapidly and has coincided with increased psychotropic medication use.
242 reased cfDNA levels were not correlated with psychotropic medications use.
243       Outpatient mental health treatment and psychotropic-medication use in children and adolescents
244  Diagnostic Interview and a questionnaire on psychotropic medications used during the previous 6 mont
245                                         Many psychotropic medications used to treat schizophrenia hav
246 median [IQR] age, 18 [14-22] years) incident psychotropic medication users.
247                                              Psychotropic medication visits increased at comparable r
248          The number of visits during which a psychotropic medication was prescribed increased from 32
249               When data from patients taking psychotropic medication were excluded from the analysis,
250 nd adjusted costs for services and dispensed psychotropic medications were calculated.
251                                              Psychotropic medications were discontinued at least 2 we
252                                              Psychotropic medications were discontinued before random
253  6 months, and who were free of hormonal and psychotropic medications were recruited into 4 study gro
254 rent immunological profiles and exposures to psychotropic medications, which should be further explor
255 ntly face the need to decide whether to take psychotropic medications while breast-feeding.
256        Primary care practitioners prescribed psychotropic medications with psychiatric consultation.
257 sociated with the prescription of at least 1 psychotropic medication, with significant increases from
258  health-related outpatient visits and use of psychotropic medications, with greater overall burden am
259 nvestigations into the benefits and risks of psychotropic medications within this population and high
260  role in outpatient mental health care while psychotropic medication without psychotherapy, though th
261 ortion of mental health outpatients received psychotropic medication without psychotherapy.
262 essant without a clear indication, 10.1% for psychotropic medications without an antipsychotic, and 1
263       In contrast, women who used prescribed psychotropic medications without specialist diagnosis ha
264  .058), and 21 patients stopped or decreased psychotropic medication (z = -2.887, p = .004).

 
Page Top